Calreticulin and type I interferon: An unsuspected connection

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Galluzzi, Lorenzo ^a,b   Kroemer, Guido ^{b,c,d,e,f,g,h}  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e INSERM   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; ATP; CD8+ cytotoxic T lymphocytes; dendritic cells; HMGB1; immunogenic cell death

Indexed keywords

CALRETICULIN; CD4 ANTIGEN; CD8 ANTIGEN; INTERFERON; LIPOCORTIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ACUTE MYELOID LEUKEMIA; CELL ACTIVATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; IONIZING RADIATION; NONHUMAN; PHOTODYNAMIC THERAPY;

EID: 85015231656     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1288334     Document Type: Editorial

References (16)

1. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003; 4:181-91; PMID:12612637; http://dx.doi.org/10.1038/nrm1052
2. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011; 11:823-36; PMID:22076556; http://dx.doi.org/10.1038/nri3084
3. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautes-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial Watch:Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015; 4:e1008866; PMID:26137404; http://dx.doi.org/10.1080/2162402X.2015.1008866
4. Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 2014; 3:e968434; PMID:25964865; http://dx.doi.org/10.4161/21624011.2014.968434
5. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3:e28518; PMID:25071979; http://dx.doi.org/10.4161/onci.28518
6. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2016; 17:97-111; PMID:27748397; http://dx.doi.org/10.1038/nri.2016.107
7. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691
8. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
9. Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res 2016; 76:1746-56; PMID:26842877; http://dx.doi.org/10.1158/0008-5472.CAN-15-1142
10. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood 2016; 128:3113-24; PMID:27802968; http://dx.doi.org/10.1182/blood-2016-08-731737
11. Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1:e104; PMID:21368877; http://dx.doi.org/10.1038/cddis.2010.82
12. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
13. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14:303-13; PMID:11290339; http://dx.doi.org/10.1016/S1074-7613(01)00111-X
14. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194:781-95; PMID:11560994; http://dx.doi.org/10.1084/jem.194.6.781
15. Chen X, Fosco D, Kline DE, Kline J. Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. Oncoimmunology 2017; In press.
16. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922